STAT3 signaling in polycystic kidney disease
نویسندگان
چکیده
منابع مشابه
STAT3 Signaling in Polycystic Kidney Disease.
Mutations in the gene coding for the integral membrane protein polycystin-1 (PC1) are the cause of most cases of autosomal-dominant polycystic kidney disease (ADPKD), a very common disease that leads to kidney failure and currently lacks approved treatment. Recent work has revealed that PC1 can regulate the transcription factor STAT3, and that STAT3 is aberrantly activated in the kidneys of ADP...
متن کاملWnt signaling in polycystic kidney disease.
Wnt signaling cascades activate morphogenetic programs that range from cell migration and proliferation to cell fate determination and stem cell renewal. These pathways enable cells to translate environmental cues into the complex cellular programs that are needed to organize tissues and build organs. Wnt signaling is essential for renal development; however, the specific molecular underpinning...
متن کاملHuman disease: Calcium signaling in polycystic kidney disease
Polycystic kidney disease results from loss of function of either of two novel proteins, polycystin-1 or polycystin-2. Recent studies show that intracellular calcium signaling is important in kidney development, and define defects in this signaling pathway as the basis of cyst formation in polycystic kidney disease.
متن کاملHeterotrimeric G protein signaling in polycystic kidney disease.
Autosomal dominant polycystic kidney disease (ADPKD) is a signalopathy of renal tubular epithelial cells caused by naturally occurring mutations in two distinct genes, polycystic kidney disease 1 (PKD1) and 2 (PKD2). Genetic variants in PKD1, which encodes the polycystin-1 (PC-1) protein, remain the predominant factor associated with the pathogenesis of nearly two-thirds of all patients diagnos...
متن کاملInhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease.
Autosomal dominant polycystic kidney disease (ADPKD), characterized by the formation of numerous kidney cysts, is caused by PKD1 or PKD2 mutations and affects 0.1% of the population. Although recent clinical studies indicate that reduction of cAMP levels slows progression of PKD, this finding has not led to an established safe and effective therapy for patients, indicating the need to find new ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Discovery Today: Disease Mechanisms
سال: 2013
ISSN: 1740-6765
DOI: 10.1016/j.ddmec.2013.03.001